Research programme: melioidosis therapeutics - Intrexon/Soligenix

Drug Profile

Research programme: melioidosis therapeutics - Intrexon/Soligenix

Alternative Names: SGX 101

Latest Information Update: 27 Aug 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intrexon Corporation; Soligenix
  • Class Monoclonal antibodies; Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Melioidosis

Most Recent Events

  • 19 Aug 2014 Preclinical trials in Melioidosis in USA (Parenteral)
  • 19 Aug 2014 Research programme: melioidosis therapeutics - Intrexon/Soligenix is available for licensing in World as of 19 Aug 2014.
  • 01 May 2013 Early research in Melioidosis in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top